Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma

Internal Medicine

Volumn 47, Issue 7, 2008, Pages 651-653

  Takahashi, Naoto ^a   Kameoka, Yoshihiro ^a   Yamanaka, Yasuo ^a   Ubukawa, Kumi ^a   Saito, Kunie ^a   Fujishima, Masumi ^a   Fujishima, Naohito ^a   Saito, Hirofumi ^a   Hirokawa, Makoto ^a   Scott, Stuart A ^b   Sawada, Kenichi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Itoraconazol oral solution; Neurotoxicity; Polymyalgia rheumatica; Vincristine

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; ITRACONAZOLE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG METABOLISM; DRUG SOLUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; ILEUS; LYMPHOMA; MALE; MYALGIA; MYCOSIS; NEUROTOXICITY; CASE REPORT; DRUG POTENTIATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SOLUTION AND SOLUBILITY; TOXICITY AND INTOXICATION;

ADMINISTRATION, ORAL; AGED; DRUG SYNERGISM; FEMALE; HUMANS; ITRACONAZOLE; LYMPHOMA; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PHARMACEUTICAL SOLUTIONS; VINCRISTINE;

EID: 44849130124     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0701     Document Type: Article

References (14)

1. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138: 705-713, 2003.
2. Marr KA, Crippa. F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103: 1527-1533, 2004.
3. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 26: 159-169, 2001.
4. Böhme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71: 311-312, 1995.
5. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 18: 137-142, 2001.
6. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 90: 1204-1207, 2001.
7. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18: 543-546, 2001.
8. Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe vincristine neurotoxicity with concomitant use of itraconazole. J Paediatr Child Health 39: 638-639, 2003.
9. Bermúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristme neurotoxicity: case report and review of literature. J Pediatr Rematol Oncol 27: 389-392, 2005.
10. Chen S, Wu D, Sun A, et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia. Am J Hematol 82: 942, 2007.
11. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34: 1317-1327, 2006.
12. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 18: 1304-1307, 1998.
13. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38: 111-180, 2000.
14. Thompson EE, Kuttab-Boulos H, Yang L, et al. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 6: 105-114, 2006.